Literature DB >> 27252475

Defining the Effectiveness of Antimalarial Chemotherapy: Investigation of the Lag in Parasite Clearance Following Drug Administration.

David S Khoury1, Deborah Cromer1, Jörg J Möhrle2, James S McCarthy3, Miles P Davenport1.   

Abstract

BACKGROUND: The emergence of drug-resistant malaria highlights the need for new agents. A desired characteristic of candidate antimalarials is rapid killing of parasites. This is typically measured by the rate of exponential clearance of parasitemia following treatment. However, this clearance rate excludes the highly variable lag phase, when the parasitemia level may increase, remain constant, or decrease. Understanding factors determining this lag phase is important for drug development.
METHODS: We assessed the kinetics of parasitemia in 112 volunteers infected with blood-stage Plasmodium falciparum and treated with 8 different antimalarials. The parasitemia level was measured by quantitative polymerase chain reaction. We analyzed the relationship between the timing of treatment in the parasite growth cycle, and whether the parasitemia level rose or fell in the first 12 or 24 hours after treatment.
RESULTS: The timing of treatment in the parasite life cycle predicted whether subjects experienced rises or falls in parasitemia level after treatment. Antimalarials were unable to prevent rises in the parasitemia level in the first 12 hours. However, in the first 24 hours after treatment, fast-acting but not slow-acting drugs reduced the parasitemia level independent of when treatment was administered.
CONCLUSIONS: The highly variable lag phase depends on the speed of action of an antimalarial and when in the periodic growth cycle it is administered.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  Plasmodium falciparum; antimalarial; blood-stage; drug efficacy; human challenge; lag phase; malaria; mathematical modeling

Mesh:

Substances:

Year:  2016        PMID: 27252475      PMCID: PMC4978373          DOI: 10.1093/infdis/jiw234

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Malaria parasites giving rise to recrudescence in vitro.

Authors:  Shusuke Nakazawa; Takashi Maoka; Haruki Uemura; Yoshihiro Ito; Hiroji Kanbara
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

2.  Effect of blood transfusion on survival among children in a Kenyan hospital.

Authors:  E M Lackritz; C C Campbell; T K Ruebush; A W Hightower; W Wakube; R W Steketee; J B Were
Journal:  Lancet       Date:  1992-08-29       Impact factor: 79.321

3.  Stage specific actions of antimalarial drugs on Plasmodium falciparum in culture.

Authors:  T G Geary; A A Divo; J B Jensen
Journal:  Am J Trop Med Hyg       Date:  1989-03       Impact factor: 2.345

4.  Indicators of life-threatening malaria in African children.

Authors:  K Marsh; D Forster; C Waruiru; I Mwangi; M Winstanley; V Marsh; C Newton; P Winstanley; P Warn; N Peshu
Journal:  N Engl J Med       Date:  1995-05-25       Impact factor: 91.245

5.  Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR.

Authors:  Louise Marquart; Mark Baker; Peter O'Rourke; James S McCarthy
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

6.  Defining the timing of action of antimalarial drugs against Plasmodium falciparum.

Authors:  Danny W Wilson; Christine Langer; Christopher D Goodman; Geoffrey I McFadden; James G Beeson
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

7.  Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.

Authors:  Arjen M Dondorp; Caterina I Fanello; Ilse C E Hendriksen; Ermelinda Gomes; Amir Seni; Kajal D Chhaganlal; Kalifa Bojang; Rasaq Olaosebikan; Nkechinyere Anunobi; Kathryn Maitland; Esther Kivaya; Tsiri Agbenyega; Samuel Blay Nguah; Jennifer Evans; Samwel Gesase; Catherine Kahabuka; George Mtove; Behzad Nadjm; Jacqueline Deen; Juliet Mwanga-Amumpaire; Margaret Nansumba; Corine Karema; Noella Umulisa; Aline Uwimana; Olugbenga A Mokuolu; Olanrewaju T Adedoyin; Wahab B R Johnson; Antoinette K Tshefu; Marie A Onyamboko; Tharisara Sakulthaew; Wirichada Pan Ngum; Kamolrat Silamut; Kasia Stepniewska; Charles J Woodrow; Delia Bethell; Bridget Wills; Martina Oneko; Tim E Peto; Lorenz von Seidlein; Nicholas P J Day; Nicholas J White
Journal:  Lancet       Date:  2010-11-07       Impact factor: 79.321

8.  A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers.

Authors:  Rebecca J Rockett; Sarah J Tozer; Chris Peatey; Seweryn Bialasiewicz; David M Whiley; Michael D Nissen; Katharine Trenholme; James S Mc Carthy; Theo P Sloots
Journal:  Malar J       Date:  2011-02-28       Impact factor: 2.979

9.  P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action.

Authors:  Laura M Sanz; Benigno Crespo; Cristina De-Cózar; Xavier C Ding; Jose L Llergo; Jeremy N Burrows; Jose F García-Bustos; Francisco-Javier Gamo
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

10.  In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border.

Authors:  Marion Barends; Anchalee Jaidee; Nopparat Khaohirun; Pratap Singhasivanon; François Nosten
Journal:  Malar J       Date:  2007-06-27       Impact factor: 2.979

View more
  8 in total

1.  Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment.

Authors:  Georges F R Radohery; Annabelle Walz; Christin Gumpp; Mohammed H Cherkaoui-Rbati; Nathalie Gobeau; Jeremy Gower; Miles P Davenport; Matthias Rottmann; James S McCarthy; Jörg J Möhrle; Maria Rebelo; Claudia Demarta-Gatsi; David S Khoury
Journal:  Antimicrob Agents Chemother       Date:  2022-06-21       Impact factor: 5.938

2.  Characteristics and Severity of Disease among 100 Cases of Imported Malaria Seen at a U.S. University Hospital, 2000-2017.

Authors:  Hana Akselrod; Matthew J Swierzbinski; Zhaonian Zheng; John Keiser; David M Parenti; Gary L Simon
Journal:  Am J Trop Med Hyg       Date:  2018-12       Impact factor: 2.345

3.  Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.

Authors:  James S McCarthy; Julie Lotharius; Thomas Rückle; Stephan Chalon; Margaret A Phillips; Suzanne Elliott; Silvana Sekuloski; Paul Griffin; Caroline L Ng; David A Fidock; Louise Marquart; Noelle S Williams; Nathalie Gobeau; Lidiya Bebrevska; Maria Rosario; Kennan Marsh; Jörg J Möhrle
Journal:  Lancet Infect Dis       Date:  2017-03-28       Impact factor: 25.071

4.  How long do rapid diagnostic tests remain positive after anti-malarial treatment?

Authors:  Ursula Dalrymple; Rohan Arambepola; Peter W Gething; Ewan Cameron
Journal:  Malar J       Date:  2018-06-08       Impact factor: 2.979

5.  Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance.

Authors:  Matthew J Grigg; Timothy William; Kim A Piera; Giri S Rajahram; Jenarun Jelip; Ammar Aziz; Jayaram Menon; Jutta Marfurt; Ric N Price; Sarah Auburn; Bridget E Barber; Tsin W Yeo; Nicholas M Anstey
Journal:  Malar J       Date:  2018-12-10       Impact factor: 2.979

6.  Artemisinin Resistance and Stage Dependency of Parasite Clearance in Falciparum Malaria.

Authors:  Benjamas Intharabut; Hugh W Kingston; Ketsanee Srinamon; Elizabeth A Ashley; Mallika Imwong; Mehul Dhorda; Charles Woodrow; Kasia Stepniewska; Kamolrat Silamut; Nicholas P J Day; Arjen M Dondorp; Nicholas J White
Journal:  J Infect Dis       Date:  2019-04-16       Impact factor: 5.226

7.  Therapeutic Efficacy of Artemether-Lumefantrine for Uncomplicated Falciparum Malaria in Northern Zambia.

Authors:  Matthew M Ippolito; Julia C Pringle; Mwiche Siame; Ben Katowa; Ozkan Aydemir; Peter O Oluoch; Liusheng Huang; Francesca T Aweeka; Jeffrey A Bailey; Jonathan J Juliano; Steven R Meshnick; Theresa A Shapiro; William J Moss; Philip E Thuma
Journal:  Am J Trop Med Hyg       Date:  2020-10-15       Impact factor: 3.707

8.  Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study.

Authors:  Azrin N Abd-Rahman; Louise Marquart; Nathalie Gobeau; Anne Kümmel; Julie A Simpson; Stephan Chalon; Jörg J Möhrle; James S McCarthy
Journal:  Clin Pharmacol Ther       Date:  2020-07-02       Impact factor: 6.903

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.